- Now available for use with both Apple and Android devices, the
app helps people track pain relief during the treatment journey
with neurostimulation devices
- Updated app provides doctors with an at-a-glance assessment of
their patients while on their treatment journey
ABBOTT
PARK, Ill., April 25,
2022 /PRNewswire/ -- Abbott (NYSE: ABT) today
announced that it has launched an upgraded version of its
NeuroSphere™ myPath™ digital health app with enhanced functionality
that will help doctors more closely track their patients as they
trial Abbott neurostimulation devices to address their chronic
pain. This upgrade is part of Abbott's commitment to connected care
technology and is intended to put people in control of their health
and facilitate better communication with their doctors. The
digital health app, which can be used with both Apple and Android
devices, provides a doctor, their staff and the patient with a
shared view of patient-reported outcome measures through each stage
of the treatment journey while trying a spinal cord
stimulation (SCS) or dorsal root ganglion (DRG) therapy device.
More than 50 million Americans live with chronic
pain.1 SCS and DRG therapy can help address chronic pain
by interrupting the pain signals traveling along the spinal cord or
the dorsal root ganglia, a cluster of nerves along the spine,
before they can reach the brain. Abbott's NeuroSphere myPath
digital health app is designed to allow a person to track and
report their pain relief and general well-being. In turn, it helps
doctors understand where patients are in the journey, and how
patients are responding to therapy to better inform their treatment
plan, a major goal of Abbott's connected care approach.
"With NeuroSphere myPath, I am able to connect with my patients
virtually because I can hone in on the precise location where they
are experiencing pain and understand whether they are receiving
relief," said Pankaj Mehta, M.D., clinical president and chief
medical officer at Pain Specialists of America in Austin, Texas. "Because the app is designed to
provide a virtual environment in which I can connect
with every patient and see where they are in the process, I
can track how each person is doing, share critical data insights
with my colleagues and help them take the next step in their
pain-relief journey."
The NeuroSphere myPath app allows people to closely track and
document their pain through a series of surveys taken virtually at
baseline and during the trial period through the app. People are
asked questions to assess their pain intensity, about the relief
and changes to physical function they experience, and their overall
mood and well-being felt with and without the device throughout the
treatment. At the end of the trial, doctors can receive a succinct
yet comprehensive end-of-trial report.
The NeuroSphere myPath app is part of a family of apps Abbott
has created under the Neurosphere name, including Neurosphere
Virtual Clinic. Neurosphere Virtual Clinic is a
first-of-its-kind technology in the U.S., giving patients the
flexibility and comfort of receiving care anywhere* by connecting
with their doctor via secure in-app video chat and an integrated
remote programming feature. It enables clinicians to prescribe new
treatment settings remotely to the patient's neurostimulation
device using the clinician programmer app and a simple and secure
remote care connection.
"Our continued advancement of the NeuroSphere myPath app is part
of Abbott's commitment to developing new connected health
technology that has the potential to bridge the gap between people
and their doctors," said Pedro Malha, vice president,
Neuromodulation, Abbott. "Both the myPath digital app and our
NeuroSphere Virtual Clinic allow us to deliver a more personalized
and proactive approach to how advanced diseases are managed that
are changing how people access healthcare around the world."
*Anywhere with a cellular or Wi-Fi connection and sufficiently
charged patient controller.
For U.S. important safety information on spinal cord
stimulation, visit
https://www.neuromodulation.abbott/int/en/neurostimulation-products/neurostimulators-chronic-pain/proclaim-elite-recharge-free-scs-system.html#isi.
For U.S. important safety information on spinal cord
stimulation, visit
https://www.neuromodulation.abbott/int/en/neurostimulation-products/neurostimulators-chronic-pain/proclaim-drg-neurostimulator-system.html#isi.
About Abbott
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 113,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn
at www.linkedin.com/company/abbott-/, on Facebook
at www.facebook.com/Abbott and on Twitter
@AbbottNews.
1.
|
Centers for Disease
Control and Prevention. Prevalence of Chronic Pain and High-Impact
Chronic Pain Among Adults – United States, 2016.
https://www.cdc.gov/mmwr/volumes/67/wr/mm6736a2.htm. Accessed March
28, 2022.
|
View original
content:https://www.prnewswire.com/news-releases/abbott-strengthens-its-connected-care-technologies-with-latest-neurosphere-mypath-digital-health-app-301530851.html
SOURCE Abbott